Immunovant Inc
IMVT
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.5B
Close$
$4.94
87.4% downside
Current Fair Value
87.4% downsideOvervalued by 87.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.50 Billion |
|---|---|
| Enterprise Value | $7.71 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.77 |
| Beta | 0.81 |
| Outstanding Shares | 205,545,373 |
Return
| Return on Equity | -73.19% |
|---|---|
| Return on Assets | -63.13% |
| Return on Invested Capital | -60.45% |
Valuation & Multiples
| P/E Ratio | -14.61 |
|---|---|
| PEG | -54.04 |
| Price to Sales | - |
| Price to Book Ratio | 13.08 |
| Enterprise Value to Revenue | 1086.11 |
| Enterprise Value to EBIT | -17.33 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.73
Average shareholder expectationRevenue Estimate
$7.09 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1536▲ 4.90% |
|---|---|
| Total Calls | 1,801,100▼ 28.30% |
| Total Puts | 276,600▲ 5.25% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 56.21%▼ 4.41% |
|---|---|
| Total Invested | $4.37B▲ 58.93% |
| Investors Holding | 239▲ 13.00% |
ESG Score
No data